Literature Review on the Immunogenicity of Herpes Zoster Vaccines
Herpes zoster is an acute viral infection caused by reactivation of varicella-zoster virus (VZV). LZV, a live, attenuated vaccine for zoster has been available in Canada for many years. A new subunit recombinant zoster vaccine (RZV) named Shingrix was approved in Canada in October 2017. This zoster vaccine immunogenicity review was done to have a comprehensive understanding of the immunogenicity of both live and subunit vaccines.
- Publisher - Current Organization Name: Public Health Agency of Canada
- Licence: Open Government Licence - Canada
Data and Resources
-
Literature Review on the Immunogenicity of Herpes Zoster VaccinesHTMLEnglish website HTML
-
Literature Review on the Immunogenicity of Herpes Zoster VaccinesHTMLFrench website HTML
Similar records